Dimitrios Chondros, Senior Vice President, Chief Medical Officer

Dr. Chondros brings to Halozyme broad experience directing complex clinical development and companion diagnostic programs toward global regulatory approvals and preparing for market entry. Dr. Chondros joined Halozyme in 2015 as Vice President of Clinical Development and assumed CMO responsibilities in 2017. Throughout his career, Dr. Chondros has managed cross functional teams across several key functions, including Clinical Science, Safety, Regulatory Affairs, Biostatistics, Research, Biomarkers, Clinical Pharmacology, Medical Affairs and Clinical Operations. He has also managed relationships with physicians and scientists across global sites.

Prior to Halozyme, he held positions of increasing responsibility at Genentech in the Product Development Oncology division and served as a member of the Antiangiogenesis and Oncology Signaling Franchise Leadership Teams. He played a leadership role for Avastin®, where he was accountable for all global development activities in gastrointestinal cancers, including the regulatory approvals for metastatic colorectal cancer. Prior to Genentech, he was Medical Director at Cell Genesys, where he directed the clinical development of an investigational immunotherapy for prostate cancer. Dr. Chondros has worked for the biopharmaceutical industry in Europe, China and USA.

Dr. Chondros studied medicine at the RWTH Aachen University in Germany and received his M.D. from the University of Zürich, Switzerland. He is a board certified general surgeon with experience as clinical trial investigator in numerous indications.


You are now leaving Halozyme.com. Halozyme is not responsible for or endorses the content of the linked site.